NCT01484184: Study to Assess Safety, Tolerability and MTD of a Central Pattern Generator-activating Tritherapy (SPINALON) in Patients With Chronic Spinal Cord Injury |
|
|
| Completed | 1/2 | 50 | Canada | SPINALON (buspirone + levodopa + cardidopa), Apo-Buspirone 10 mg tablets (DIN 02211076), Sinemet 100/25 mg tablets (DIN 00513997) | Nordic Life Science Pipeline Inc., United States Department of Defense | Spinal Cord Injury | 08/15 | 08/15 | | |
